(Q33965047)

English

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

author name string

James Shepherd

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Donald B Hunninghake

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Philip Barter

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

James M McKenney

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Howard G Hutchinson

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5A

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

11C-17C; discussion 17C-19C

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900004-3

7 January 2021

Identifiers

10.1016/S0002-9149(03)00004-3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33965047&oldid=1603749140"